Showing 6911-6920 of 9343 results for "".
Updating Approaches to Psoriasis
https://practicaldermatology.com/topics/psoriasis/evaluating-the-state-of-psoriasis-care/21660/Recent guidelines from the National Psoriasis Foundation point to new directions in research and therapy that will continue to shape psoriasis therapy.Electronic Health Records
https://practicaldermatology.com/topics/practice-management/electronic-health-records/19383/Dr. Kaufmann discusses EHRs, government incentives, and the importance of choosing a system that is right for each practice. He offers tips for residents and young physicians for choosing and using electronic health records.Body Contouring
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/body-contouring/19413/Dr. Amy Derick discusses the latest way to achieve a leaner, more sculpted look with CoolSculpting® by Zeltiq®.Atopic Dermatitis and Psoriasis: Treatments, Considerations, and What’s Coming
https://practicaldermatology.com/programs/practical-dermatology/atopic-dermatitis-and-psoriasis-treatments-considerations-and-whats-coming/24038/Atopic dermatitis (AD) and plaque psoriasis (PsO) are two of the most common cutaneous conditions we treat in dermatology. While these chronic inflammatory disorders have similarities, regarding chronic skin disease burden and impact on quality of life, they may diverge when considering clinical preReclaiming “Quality” in Dermatology
https://practicaldermatology.com/topics/practice-management/reclaiming-quality-in-dermatology/23432/Dermatologists know quality care when they see it. It’s time to take an active role in defining meaningful quality measures.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Diversity in the Dermatology Workforce: What Can We Do?
https://practicaldermatology.com/topics/practice-management/diversity-in-the-dermatology-workforce-what-can-we-do/23057/Medicine in general lacks workforce diversity. Dermatology fares worse than other specialties. Here’s a closer look at the problem.PDT in Action: New Options for Actinic Keratosis
https://practicaldermatology.com/series/pdt-in-practice/pdt-in-action-new-options-for-actinic-keratosis/20210/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, shares insights into the use of photodynamic therapy (PDT) in his practice and how PDT has impacted the options for the treatment of actinic keratosis.Revenue Cycle Management: What Physicians and Administrators Need to Know
https://practicaldermatology.com/topics/practice-management/revenue-cycle-management-what-physicians-and-administrators-need-to-know/23536/The latest generation of RCM software can benefit practices in multiple ways.What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis
https://practicaldermatology.com/topics/psoriasis/what-does-efficacy-cost-evidence-for-relative-cost-effectiveness-of-biologic-therapies-for-psoriasis/23128/Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.